Loading stock data…
$36.41-0.01 (-0.01%)
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.
Septerna, Inc. in the Healthcare sector is trading at $36.41 with a market capitalization of $1.7B. Wall Street consensus targets $54.22 (9 analysts), implying a +48.9% move over the next 12 months. The stock is currently 29% below its 52-week high of $51.10, remaining 16.6% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $26.75M↑ | $26.52M↑ | $24.12M↑ | $21.50M↑ | $119,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$16.84M↓ | -$13.30M↑ | -$16.02M↓ | -$9.89M↑ | -$28.98M |
| Net Income | -$13.03M↓ | -$8.64M↑ | -$10.74M↓ | $8.17M↑ | -$24.84M |
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R P...